GleamWall
中文EN

NXTS Nexentis Technologies Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1789192 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY18.6%
TTM net income YoY-19.7%
TTM EPS YoY-31,123.8%
Revenue 3-yr CAGR-16.6%
Net income 3-yr CAGR—

Margins

Gross margin65.2%
Operating margin-2,119.7%
Net margin-3,187.1%
FCF margin—
EBITDA margin-2,114.4%

Returns

ROE-92.5%
ROA-78.9%
ROIC (approx.)-126.3%
Asset turnover0.02x

Leverage & solvency

Liabilities / assets21.3%
Debt / equity0.00x
Current ratio4.21x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.42x
Accruals ratio-45.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q2*2025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————$2,000$0$66,000$140,519
Cost of revenue————$2,000$2,000$14,000$54,477
Gross profit————$0-$2,000$52,000$86,042
R&D expense$288,000$373,000$275,000$98,000$52,000$9,000$20,000$119,034
SG&A expense$985,000$1.26M$1.90M$492,000$1.07M$2.63M$503,000$477,000
Operating income-$1.23M-$1.88M-$8.22M$549,000-$1.07M-$2.63M-$503,000-$219,000
Pretax income$4.98M-$11.18M-$7.45M$1.27M$616,000-$4.39M-$1.12M—
Income tax-$24,000-$23,000-$23,000—————
Net income$5.03M-$11.14M-$6.58M$1.27M$429,000-$4.51M-$1.19M-$1.37M
EBITDA-$1.13M-$1.77M-$8.14M$612,000-$1.07M-$2.62M-$500,000-$215,957
EPS (basic)17.12-13.66-10.74—15.47-44.26-18.00—
EPS (diluted)-0.29-13.66-10.74—11.59-44.26-85.25—
Weighted avg. shares (diluted)482,401816,136612,715—28,432101,862101,975—
Banking
Net interest income—————$127,000——
Balance sheet
Cash & equivalents$2.84M$7.62M$4.30M$3.83M$6.07M$3.16M$2.75M$2.21M
Short-term investments$640,000$1.26M$1.90M$239,000$240,000$271,000$230,000$307,000
Receivables——$130,000$134,000$2,000$195,000$195,000$137,000
Inventory————$16,000$16,000$15,000$21,000
Current assets$7.64M$10.39M$8.22M$6.01M$8.66M$5.02M$4.33M$3.45M
PP&E, net$82,000$86,000$89,000$26,000$40,000$43,000$45,000$48,000
Goodwill———$6.29M————
Intangibles$4.12M$4.23M$4.33M$4.43M————
Total assets$15.49M$18.69M$16.40M$20.41M$11.03M$7.75M$7.37M$5.46M
Current liabilities$1.96M$2.80M$1.74M$1.43M$2.06M$1.06M$976,000$892,000
Short-term debt—$215,000$364,000$740,000$1.22M$1.23M$651—
Total liabilities$2.72M$16.91M$3.54M$4.67M$2.35M$2.20M$3.67M$892,000
Shareholders' equity$12.90M$1.91M$12.97M$16.01M$8.93M$5.76M$3.94M$4.75M
Shares outstanding297,8851.45M730,45979,5041.37M30.10M17.81M344,741
Cash flow statement
Operating cash flow-$1.23M-$539,000-$1.42M-$1.50M-$974,000-$528,000-$809,000-$491,852
Capital expenditure$0$1,000$71,000—————
Free cash flow-$1.23M-$540,000-$1.49M—————
Investing cash flow-$2.79M-$110,000-$450,000-$1.33M-$273,000-$449,000-$1.18M-$515,956
Financing cash flow-$770,000$3.95M$2.20M$759,000$4.16M$1.40M$2.53M$445,968
Depreciation & amortization$107,000$106,000$82,000$63,000$3,000$2,000$3,000$3,043
Stock-based compensation$217,000$70,000$90,000$90,000$0———

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.